MA46440B1 - Solvate de diméthylsulfoxyde n-(3-[3-cyclopropyl-5-(2-fluoro-4-iodophénylamino)-6,8-diméthyl-2,4,7-trioxo-3,4,6,7-tétrahydro-2n-pyrido[4,3-d]pyrimidin-1-yl]-phényl)- cyclopropanecarboxamide utilisé en tant que inhibiteur de mek1/2 - Google Patents

Solvate de diméthylsulfoxyde n-(3-[3-cyclopropyl-5-(2-fluoro-4-iodophénylamino)-6,8-diméthyl-2,4,7-trioxo-3,4,6,7-tétrahydro-2n-pyrido[4,3-d]pyrimidin-1-yl]-phényl)- cyclopropanecarboxamide utilisé en tant que inhibiteur de mek1/2

Info

Publication number
MA46440B1
MA46440B1 MA46440A MA46440A MA46440B1 MA 46440 B1 MA46440 B1 MA 46440B1 MA 46440 A MA46440 A MA 46440A MA 46440 A MA46440 A MA 46440A MA 46440 B1 MA46440 B1 MA 46440B1
Authority
MA
Morocco
Prior art keywords
mek1
iodophenylamino
trioxo
cyclopropanecarboxamide
pyrido
Prior art date
Application number
MA46440A
Other languages
English (en)
Other versions
MA46440A (fr
Inventor
Alexey Evgenievich Repik
Alexandre Vasilievich Ivachtchenko
Vasily Gennadievich Ignatiev
Mikhail Airatovich Chafeev
Original Assignee
R Pharm Joint Stock Company R Pharm Jsc
Alexey Evgenievich Repik
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Pharm Joint Stock Company R Pharm Jsc, Alexey Evgenievich Repik filed Critical R Pharm Joint Stock Company R Pharm Jsc
Publication of MA46440A publication Critical patent/MA46440A/fr
Publication of MA46440B1 publication Critical patent/MA46440B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Le but de la présente invention est de créer de nouveaux inhibiteurs de mek1, mek2 et mek1/2 qui ont une toxicité plus faible en dosage à long terme. Ce but est atteint par le nouveau composé n-{3-[3-cyclopropyl-5-(2-fluoro-4-iodophénylamino)-6,8-diméthyl-2,4,7-trioxo-3,4,6, solvat de diméthylsulfoxyde de 7-tétrahydro-2h-pyrido[4,3-d]pyrimidin-1-yl]-phényl}-cyclopropanecarboxamide de formule 1
MA46440A 2016-10-10 2016-12-12 Solvate de diméthylsulfoxyde n-(3-[3-cyclopropyl-5-(2-fluoro-4-iodophénylamino)-6,8-diméthyl-2,4,7-trioxo-3,4,6,7-tétrahydro-2n-pyrido[4,3-d]pyrimidin-1-yl]-phényl)- cyclopropanecarboxamide utilisé en tant que inhibiteur de mek1/2 MA46440B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2016139641A RU2627692C1 (ru) 2016-10-10 2016-10-10 N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2
PCT/RU2016/000862 WO2018070900A1 (fr) 2016-10-10 2016-12-12 Solvate de diméthylsulfoxyde n-{3-[3-cyclopropyl-5-(2-fluoro-4-iodophénylamino)-6,8-diméthyl-2,4,7-trioxo-3,4,6,7-tétrahydro-2n-pyrido[4,3-d]pyrimidin-1-yl]-phényl}- cyclopropanecarboxamide utilisé en tant que inhibiteur de mek1/2

Publications (2)

Publication Number Publication Date
MA46440A MA46440A (fr) 2021-06-02
MA46440B1 true MA46440B1 (fr) 2021-11-30

Family

ID=59641667

Family Applications (1)

Application Number Title Priority Date Filing Date
MA46440A MA46440B1 (fr) 2016-10-10 2016-12-12 Solvate de diméthylsulfoxyde n-(3-[3-cyclopropyl-5-(2-fluoro-4-iodophénylamino)-6,8-diméthyl-2,4,7-trioxo-3,4,6,7-tétrahydro-2n-pyrido[4,3-d]pyrimidin-1-yl]-phényl)- cyclopropanecarboxamide utilisé en tant que inhibiteur de mek1/2

Country Status (27)

Country Link
US (1) US10738049B2 (fr)
EP (1) EP3524601B1 (fr)
JP (1) JP6909299B2 (fr)
KR (1) KR102387288B1 (fr)
CN (1) CN110012668B (fr)
AU (1) AU2016426350B2 (fr)
BR (1) BR112019007223A2 (fr)
CA (1) CA3039524A1 (fr)
CO (1) CO2019004688A2 (fr)
CY (1) CY1125283T1 (fr)
DK (1) DK3524601T3 (fr)
EA (1) EA037939B1 (fr)
ES (1) ES2898026T3 (fr)
HR (1) HRP20211693T1 (fr)
HU (1) HUE056490T2 (fr)
LT (1) LT3524601T (fr)
MA (1) MA46440B1 (fr)
MD (1) MD3524601T2 (fr)
MX (1) MX2019004137A (fr)
PH (1) PH12019500721A1 (fr)
PL (1) PL3524601T3 (fr)
PT (1) PT3524601T (fr)
RS (1) RS62604B1 (fr)
RU (1) RU2627692C1 (fr)
SI (1) SI3524601T1 (fr)
WO (1) WO2018070900A1 (fr)
ZA (1) ZA201902861B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230293463A1 (en) 2022-03-17 2023-09-21 SpringWorks Therapeutics Inc. Treatment of cutaneous neurofibromas with Mirdametinib
CN114853754B (zh) * 2022-05-23 2023-04-18 云白药征武科技(上海)有限公司 一种硫代酰胺衍生物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
CN101912400B (zh) 2004-06-11 2013-06-26 日本烟草产业株式会社 用于治疗癌症的5-氨基-2,4,7-三氧代-3,4,7,8-四氢-2H-吡啶并[2,3-d]嘧啶衍生物和相关化合物
TWI505828B (zh) * 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
CA2889530A1 (fr) * 2012-10-25 2014-05-01 Glaxosmithkline Llc Combinaison
RU2605400C1 (ru) * 2015-11-13 2016-12-20 ЗАО "Р-Фарм" ПРОИЗВОДНЫЕ 1-(3-АМИНОФЕНИЛ)-6,8-ДИМЕТИЛ-5-(4-ИОД-2-ФТОР-ФЕНИЛАМИНО)-3-ЦИКЛОПРОПИЛ-1H,6H-ПИРИДО[4,3-d]ПИРИМИДИН-2,4,7-ТРИОНА В КАЧЕСТВЕ ИНГИБИТОРОВ МЕК1/2

Also Published As

Publication number Publication date
DK3524601T3 (da) 2021-11-08
SI3524601T1 (sl) 2022-02-28
EP3524601A4 (fr) 2020-03-11
WO2018070900A1 (fr) 2018-04-19
US20190233415A1 (en) 2019-08-01
KR20190062512A (ko) 2019-06-05
EA201900158A1 (ru) 2019-08-30
RS62604B1 (sr) 2021-12-31
PH12019500721A1 (en) 2019-12-02
ZA201902861B (en) 2021-06-30
JP2019531350A (ja) 2019-10-31
HUE056490T2 (hu) 2022-02-28
KR102387288B1 (ko) 2022-04-14
PT3524601T (pt) 2021-11-03
HRP20211693T1 (hr) 2022-02-04
CY1125283T1 (el) 2023-03-24
JP6909299B2 (ja) 2021-07-28
ES2898026T3 (es) 2022-03-03
US10738049B2 (en) 2020-08-11
AU2016426350B2 (en) 2020-08-27
MX2019004137A (es) 2019-09-26
EP3524601A1 (fr) 2019-08-14
EA037939B1 (ru) 2021-06-09
CA3039524A1 (fr) 2018-04-19
RU2627692C1 (ru) 2017-08-10
EP3524601B1 (fr) 2021-10-13
LT3524601T (lt) 2021-12-27
MD3524601T2 (ro) 2022-02-28
CO2019004688A2 (es) 2019-05-21
CN110012668B (zh) 2021-11-26
AU2016426350A1 (en) 2019-05-30
CN110012668A (zh) 2019-07-12
PL3524601T3 (pl) 2022-03-21
MA46440A (fr) 2021-06-02
BR112019007223A2 (pt) 2019-07-02

Similar Documents

Publication Publication Date Title
CL2019000819A1 (es) Compuestos y composiciones para inhibir la actividad arginasa. (divisional solicitud 201801134)
CL2020001271A1 (es) Inhibidores de kras g12c
ECSP18083519A (es) Inhibidores de bromodominios
EA201791563A1 (ru) Замещенные нуклеозидные производные, полезные в качестве агентов против рака
CY1120581T1 (el) Ενωσεις και μεθοδοι χρησης τους
CL2019001993A1 (es) Inhibidores selectivos de jak1.
EA201691916A1 (ru) Биарильные ингибиторы киназы
UY35834A (es) Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon
AR107529A1 (es) Compuestos, composiciones y métodos para la estratificación de pacientes de cáncer y su tratamiento
EA201691397A1 (ru) Хинолиновые ингибиторы киназы
BR112018008506B8 (pt) Compostos inibidores do fator xia, composição farmacêutica e usos dos mesmos
ECSP18018793A (es) Compuestos útiles para inhibir ror-gamma-t
MX2018008307A (es) Derivado de ascoclorina y uso del mismo como activador de proteina cinasa activada por adenosin monofosfato (ampk).
CO2018004572A2 (es) Inhibidores de calicreína plasmática humana
MA46440B1 (fr) Solvate de diméthylsulfoxyde n-(3-[3-cyclopropyl-5-(2-fluoro-4-iodophénylamino)-6,8-diméthyl-2,4,7-trioxo-3,4,6,7-tétrahydro-2n-pyrido[4,3-d]pyrimidin-1-yl]-phényl)- cyclopropanecarboxamide utilisé en tant que inhibiteur de mek1/2
CY1123880T1 (el) Καινοτομοι 5-ητ2 ανταγωνιστες
BR112017005113A2 (pt) composto de fórmula geral (i), método para preparar um composto de fórmula geral (i), método para preparar um composto de fórmula geral (iv), composição farmacêutica para o tratamento de doenças relacionadas com atividades anormais de jak3 e/ou jak1 quinase, usos do composto, e usos da composição farmacêutica
CU20190002A7 (es) Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1 para el tratamiento del cáncer y composiciones farmacéuticas que los comprenden
MA47198A (fr) Combinaison d'un inhibiteur de mcl-1 et d'un composé de taxane, ses utilisations et compositions pharmaceutiques la comprenant
CY1125039T1 (el) Νεα χρηση του ν,ν-δις-2-μερκαπτοαιθυλ ισοφθαλαμιδιου
EA201792676A1 (ru) Ингибиторы jak1
AR107163A1 (es) Inhibidores de quinasa
EA202091548A1 (ru) Несимметричные производные полифенолов динафталинового ряда, способ их получения и применение
TH1901002609A (th) สารประกอบไพริโดนในฐานะเป็นสารยับยั้งc-met
EA201892498A1 (ru) Замещенные карбонуклеозидные производные, приемлемые в качестве противораковых агентов